Environmental, social and governance

Being a responsible business means getting ahead of disease together in the right way.

We consider environmental, social and governance (ESG) impacts across everything we do, from the lab to the patient.

ESG is embedded in our strategy and supports our sustainable performance and long-term growth. It helps us build trust with and deliver returns to our stakeholders, reduce risk to our operations and deliver positive social impact.

Quarterly ESG updates

An overview of our ESG approach and a summary of activity, hot topics and news flow from the quarter

Our six ESG focus areas

We have six ESG focus areas addressing what matters most to our business and to our stakeholders. These focus areas address what is most material to our business and the issues that matter the most to our stakeholders.



We are making our products affordable and available to more people around the world through responsible pricing, strategic access programmes and partnerships.

Global health and health security

Global health and health security

We are committed to using our science, our partnerships, and the knowledge we’ve gained from addressing the world’s biggest health challenges to improve health globally.



We are committed to work towards a net zero, nature positive, healthier planet, with ambitious goals set for 2030 and 2045.

Diversity, equity and inclusion

Diversity, equity and inclusion

Our work supports the health of all kinds of people. To meet our diverse patient’s needs better, we need diversity in our clinical trials and to support our own people to thrive as part of an inclusive team.

Ethical standards

Ethical standards

Our culture guides our people to do the right thing and act on any concerns they have.

Product governance

Product governance

Ensuring the quality, safety and reliable supply of our products is critical to our purpose of uniting science, talent and technology to get ahead of disease together.

ESG investor education events

Clinical Trial Diversity

Download audio
06 June 2023

Alberto Fernandez, SVP of Global Clinical Operations at GSK and Dr. Kimberly Smith, SVP and Head of R&D at ViiV Healthcare, provided insights on the importance of clinical trial diversity and gave an overview of GSK’s work to ensure clinical trials reflect the populations most impacted by a disease.

Woman in a black dress

Claire Lund, Vice President Environmental Sustainability, hosted our first ESG Investor Education Event focusing on our environment strategy.

Our ESG Performance Rating

Our ESG Performance Rating is one of our corporate KPIs and measures progress against key metrics aligned to each of our six focus areas. The metrics were developed with stakeholder input, and our understanding of the key issues for our industry and our company. We are committed to ensuring that the rating responds to stakeholder expectations, so we will continue to review the metrics as our business, and external expectations, change.

The GSK Leadership Team (GLT) is accountable for delivering progress against the metrics and regularly reviews performance along with the Board’s Corporate Responsibility Committee (CRC). Each individual metric is assessed as either: on track (metric met or exceeded); on track with work to do (at least 80% of metric has been achieved); or off track (metric missed by more than 20%). To calculate our overall ESG Performance Rating, performance across all metrics is aggregated to a single score. 

In 2022, we tracked 23 performance metrics in our ESG Performance Rating (summarised on pages 5 and 6 of our ESG Performance Report). Our performance against the rating in 2022 was ‘on track’, based on 83% of all performance metrics being met or exceeded.

ESG Performance Report 2022

Download to find out more about our approach to ESG and progress in 2022

ESG Performance Report 2022 (PDF, 1.2MB)

External ESG ratings 

We have maintained our acknowledged leadership in ESG, and this continues to be a key driver in our goal to deliver health impact and shareholder returns. Detailed below is how we perform in key ESG ratings that we are frequently asked about by investors.

External benchmarking Current rating
Previous rating
S&P Global's Corporate Sustainability Assessment  86  88 2nd in the pharmaceutical industry group; Assessment conducted annually, current score based on 2022 submission
Access to Medicines Index 4.06 4.23 Led the bi-annual index since its inception in 2008; Updated bi-annually, current results from Nov 2022
Antimicrobial Resistance Benchmark 84% 86% Led the bi-annual benchmark since its inception in 2018; Current ranking updated Nov 2021
CDP Climate change A- A- Updated annually, current score updated Dec 2022 
CDP Water security B B Updated annually, current score updated Dec 2022 
CDP Forests (palm oil) A- B Updated annually, current score updated Dec 2022 
CDP Forests (timber) B B Updated annually, current score updated Dec 2022 
CDP Supplier engagement rating Leader Leader Updated annually, current score updated Mar 2023
Sustainalytics 18.6 18.8 2nd percentile in pharma subindustry group; Lower score represents lower risk. Current ranking updated Apr 2022
MSCI AA AA Last rating action date: Nov 2022
Moody's ESG solutions 61 61 2nd in the pharmaceutical sector; Current score updated Sept 2021
ISS Corporate Rating B+ B+ Current score updated June 2023
FTSE4Good Member  Member  Member since 2004, latest review in June 2023
ShareAction’s Workforce Disclosure Initiative  77% 75% Current score updated Feb 2023

Scores as at July 2023

Man in a suit smiling


We are committed to operating at the highest standards of corporate governance. We believe our governance structure underpins our ability to deliver the Group's strategy to create long-term value and benefit for our shareholders and stakeholders.

View information on how GSK is governed, including details on our Board Committees and Management Committees, global compliance and Policies, codes and standards on our Governance section.

Our corporate governance

Risk management

Identifying, evaluating and managing risks

Our risk management and internal control framework is well embedded and provides the ability for the Board to evaluate and oversee how the company manages principal and emerging risks in line with our long-term objectives. We have a company-wide policy that sets out the requirements, roles and responsibilities for the management and governance of risks, controls and supporting guidance on the essential elements of our internal control framework. We routinely evaluate our framework for improvements.


The Board oversees our risk management system and establishes our risk appetite, supported by the Audit & Risk Committee (ARC). The Corporate Responsibility Committee (CRC) and Science Committee further assess the effectiveness of risk management strategies pertinent to their defined remits. Our Risk Oversight & Compliance Council (ROCC) helps the ARC and CRC to oversee the risks, and the strategies used to address them. Risk management and compliance boards across the Group promote the ‘tone from the top’. They also establish our risk culture and oversee the effectiveness of risk management activities, as well as communicating information about internal controls.

Our business is accountable for delivering on its objectives in line with its established risk appetite. An Enterprise Risk Owner is responsible for each principal risk, with oversight by a GLT member. Risk owners report risk and mitigation to ROCC, the GLT and the appropriate Board committee. Legal and Compliance support these efforts by advising on our business strategies, activities, risks and controls, and Audit & Assurance provides assessments of the adequacy and effectiveness of our framework.

Considering current and emerging risks

We continuously evaluate our risks. Our risk assessment process considers the likelihood and impact of risks, and the timescale over which a risk could occur. We consider both current and emerging risks that could affect our ability to achieve our long-term objectives. Emerging risks are those on the three-year horizon, in line with our viability statement. We also define risks in this way if we need to know more about how likely they are to materialise, or what impact they’d have if they did. We will evaluate if additional investigation is required before classifying them as principal risks.

Risk management and compliance boards at all levels of the organisation identify emerging risks on an ongoing basis, and ROCC discusses emerging risks at each meeting. We also scan the risk horizon throughout the year to identify external trends that may be opportunities and/or emerging risks and monitor our business activities and internal environment for new, emerging and changing risks.

ROCC conducts an annual risk review to assess principal and emerging risks for the company. This review is supported by extensive analysis of external trends and insights, senior level interviews and recommendations from risk management and compliance boards and risk owners. ROCC shares this annual review with the ARC and Board for assessment and this forms the basis for the following year’s risk management focus.

2023 principal risks summary

We outline below the principal risks and uncertainties relevant to GSK’s business, financial condition and operations that may affect our performance and ability to achieve our objectives. These are the risks that we believe could cause our actual results to differ materially from expected and historical results. Operating in the pharmaceutical sector carries various inherent risks and uncertainties that may affect our business.

Patient safety

The risk that GSK, including our third parties, fails to appropriately collect, assess, follow up, or report human safety information, including adverse events, from all potential sources or that GSK potentially fails to appropriately act on any relevant findings that may affect the benefit-risk profile of a medicine or vaccine in a timely manner.

Back to top

Product quality

The risk that GSK or our third parties potentially fail to ensure appropriate controls and governance of quality for development and commercial products are in place; compliance with industry practices and regulations in manufacturing and distribution activities; and terms of GSK product licenses and supporting regulatory activities are met.

Back to top

Financial controls and reporting

The risk that GSK fails to comply with current tax laws; fails to report accurate financial information in compliance with accounting standards and applicable legislation; or incurs significant losses due to treasury activities.

Back to top

Legal matters

The risk that GSK or our third parties potentially fail to comply with certain legal requirements for the development, supply and commercialisation of our products and operation of business, and specifically in relation to requirements for competition law, anti-bribery and corruption, and sanctions. Any failure to meet compliance and legal standards for these particular areas could lead to increasing scrutiny and enforcement from government agencies.

Back to top

Commercial practices

Scientific and patient engagement

The risk that GSK or our third parties potentially fail to engage externally to gain insights, educate and communicate on the science of our medicines and associated disease areas, and provide grants and donations in a legitimate and transparent manner compliant with laws, regulations, industry codes and internal controls and requirements.

Back to top

Data ethics and privacy

The risk that GSK or our third parties potentially fail to ethically collect; use; re-use through artificial intelligence, data analytics or automation; secure; share and destroy personal information in accordance with laws, regulations, and internal controls and requirements.

Back to top

Research practices

Environment, health and safety (EHS)

The risk that GSK or our third parties potentially fail to ensure appropriate controls and governance of the organization's assets, facilities, infrastructure, and business activities, including execution of hazardous activities, handling of hazardous materials, or release of substances harmful to the environment that disrupts supply or harms employees, third parties or the environment.


Back to top

Information and cyber security

The risk that GSK or our third parties potentially fail to ensure appropriate controls and governance to identify, protect, detect, respond, and recover from cyber incidents through unauthorised access, disclosure, theft, unavailability or corruption of GSK's information, key systems, or technology infrastructure in accordance with applicable laws, regulations, industry standards, internal controls and requirements.

Back to top

Supply continuity

The risk that GSK or our third parties potentially fail to deliver a continuous supply of compliant finished product or respond effectively to a crisis incident in a timely manner to recover and sustain critical supply operations.

Back to top

Find more information in the sections on Risk management (page 51) and Principal risks and uncertainties (page 285) in our Annual Report. You can also explore our Code and all our policies: